Withdrawals due to adverse events · adult patients with refractory Crohn's disease
Methotrexate may leads to higher withdrawal due to adverse event (Feagan 1995) compared with placebo (low certainty).
3 findings from 1 review
RR 8 [1.09, 58.51]
1 study · 141 participants
Low
RR 3 [0.13, 70.42]
1 study · 52 participants
Low
RR 8.31 [0.46, 149.21]
1 study · 33 participants
Low
Failure to enter remission or possible remission at 16 weeks (Arora 1999) · adult patients with refractory Crohn's disease
Methotrexate showed no clear difference in failure to enter remission or possible remission at 24‐36 weeks… compared with 6‐MP or azathioprine (low certainty).
3 findings from 1 review
RR 1.36 [0.97, 1.92]
1 study · 58 participants
Low
RR 3.2 [0.37, 27.49]
1 study · 31 participants
Very low
RR 1.2 [0.63, 2.29]
1 study · 54 participants
Very low
Remission and complete withdrawal from steroids · patients with induction of remission in ulcerative colitis
Methotrexate showed no clear difference in remission and complete withdrawal from steroids compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · patients with induction of remission in ulcerative colitis
It is very uncertain whether methotrexate changes proportion of patients achieved clinical remission compared with 6‐mercaptopurine (very low certainty).
1 finding from 1 review
Clinical remission · patients with induction of remission in ulcerative colitis
It is very uncertain whether methotrexate changes proportion of patients achieved clinical remission compared with 5‐aminosalicylic acid (5‐ASA) (very low certainty).
1 finding from 1 review
Maintenance of clinical remission · Participants with Crohn's disease in remission
It is very uncertain whether methotrexate changes proportion of patients maintaining clinical remission compared with 6‐mercaptopurine (very low certainty).
1 finding from 1 review
Proportion of participants with confirmed macular edema (lower number of events is better) · NIIPPU
It is very uncertain whether methotrexate changes proportion of participants with confirmed macular edema (lower… compared with mycophenolate (very low certainty).
1 finding from 1 review
Proportion of participants achieving steroid‐sparing control (higher number of events is better) · NIIPPU
Methotrexate probably leads to higher proportion of participants achieving steroid‐sparing control§… compared with mycophenolate (moderate certainty).
1 finding from 1 review
Proportion of participants experiencing complications or requiring cessation of medication (lower number of events is better) · NIIPPU
Methotrexate showed no clear difference in proportion of participants experiencing complications or requiring… compared with mycophenolate (low certainty).
1 finding from 1 review
Proportion of participants achieving control of inflammation (higher number of events is better) · NIIPPU
Methotrexate probably leads to higher proportion of participants achieving control of inflammation§… compared with mycophenolate (moderate certainty).
1 finding from 1 review
Change in BCVA (lower logMAR indicate better vision) · NIIPPU
1 finding from 1 review
Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart) (higher scores indicate better vision) · NIIPPU
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants able to reduce corticosteroid or IVIg dose by more than 20% · people with CIDP
Methotrexate showed no clear difference in participants able to reduce corticosteroid or IVIg dose by more than… compared with placebo (moderate certainty).
1 finding from 1 review
Change in disability after 26 or more weeks Overall Neuropathy Limitation Scale. Scale from: 0 to 12. · people with CIDP
1 finding from 1 review
Change in disability after 26 or more weeks Amsterdam Linear Disability Scale. Scale from: 0 to 100. · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Muscle strength · people with inclusion body myositis
2 findings from 1 review
Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review